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Abstract Human CBS1 is a methionine sulfoxide reductase of
type B (MSRB) as it speci¢cally reduced Met-R-SO in peptides
with dithiothreitol or the thioredoxin system as reductants. Mu-
tation C169S in the active site completely abolished enzymatic
activity, while mutation W110A only reduced activity and
C105S had no e¡ect. Like human MSRA, hCBS1 showed in
vivo reducing activity coexpressed with the Drosophila ShC/B
potassium channel in oocytes, by accelerating the overall inac-
tivation time course. hCBS1-encoding mRNA is most abundant
in muscle tissues, especially in the heart and thereby shows an
expression pattern di¡erent to the human MSRA. 1 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Reactive oxygen species (ROS) oxidize a variety of cellular
constituents and are implicated in numerous physiological and
pathophysiological phenomena. One of the targets of ROS
and cellular oxidants in proteins are methionine residues, as
they are easily oxidized to methionine sulfoxide (MetO),
which exists in two di¡erent stereoisomers, L-Met-R-SO and
L-Met-S-SO, under physiological conditions [1,2]. Met oxida-
tion is reversed by stereoselective methionine sulfoxide reduc-
tases (MSRA and MSRB) which are coupled via thioredoxin
(TRX) to the cellular redox system [3].
Most of the known MetO-reducing enzymes have signi¢-
cant homology to the recently crystallized bovine and Esche-
richia coli MSRA [4,5] and selectively reduce the L-Met-S-SO
stereoisomer [6]. They share a conserved amino acid stretch
(GCFWG) in the active center, in which the three central
residues are indispensable for enzyme function [7]. In contrast
to bacterial and yeast MSRA, all thus far isolated mammalian
MSRA sequences have an N-terminal extension of about 20
residues targeting the enzymes to mitochondria, where they
may play an important role in decreasing the cellular ROS
level [8].
Knowledge about mechanisms leading to reduction of the
R stereoisomer L-Met-R-SO is a prerequisite for understand-
ing how oxidatively damaged proteins are completely repaired
within the cellular redox system. The ¢rst MSRB enzymes
known to stereoselectively reduce L-Met-R-SO were recently
identi¢ed, the E. coli YEAA [9] and the mouse SELR seleno-
protein [10]. PILB, found in various pathogenic bacteria such
as Neisseria, contains both an MSRA and an MSRB domain
[11]. hCBS1, a human protein, whose gene was identi¢ed in a
human eye ciliary body cDNA library [12], shares 59% ho-
mology to YEAA. It is not a seleno-protein and is only 42%
identical to SELR. Like YEAA and SELR, it is a homolog of
the recently crystallized C-terminal MSRB domain of PILB
(42% identity to hCBS1), which has been shown to reduce
L-Met-R-SO [13]. Here we studied the enzymatic activity of
hCBS1 in vitro using an assay based on MetO-containing
peptides and their mass determination using mass spectrome-
try. In vivo activity was estimated using the previously de-
scribed ShC/B voltage-gated potassium channel assay
[14,15]. Furthermore, we probed the active sites of hCBS1,
which di¡er in part from the active site of the crystallized
PILB-MSRB [13], by site-directed mutagenesis and explored
hCBS1 tissue distribution.
2. Materials and methods
2.1. Construction of expression vectors and protein expression
The human cbs1 ORF was ampli¢ed from a human lung cDNA
library (BD Biosciences, Palo Alto, CA, USA) using speci¢c primers
based on the published cDNA sequence [12] (5P-agcgggtaccATGGC-
GCGGCTCCTCTGGTGGC; 3P-gtaagcttCAGTGTTTCCTTGGTT-
GAACTTCAAAGC). For protein expression using the Ni-NTA
method the ORF was cloned into the pQE30 expression vector (Qia-
gen, Hilden, Germany). A truncated version of the cbs1 ORF allowing
the expression of His6-tagged CBS1v(1-22) was ampli¢ed by using a
speci¢c primer (gagctcGGCCAAGCGGGCGGCGGGCC) together
with the 3P primer from above and ligated into the pQE30 vector as
well. H6-MSRAv(1-22) was expressed as control as previously de-
scribed [8]. PCR-based site-directed mutagenesis was applied to intro-
duce mutations C105S, W110A, and C169S. When referring to re-
combinant protein, hCBS1 denotes H6-hCBS1v(1-22) and hMSRA
H6-MSRAv(1-22) throughout this article.
2.2. MSR enzyme activity assay
MSR activity was assayed using synthetic peptides with the se-
quence KIFM(O)K (MW 723 Da). 100^200 WM peptide was incuba-
ted with recombinant reductases in 50 mM Tris/HCl, pH 7.4, at 37‡C.
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As electron donor for the MSR enzymes either 15 mM dithiothreitol
(DTT) or the physiological TRX system (5 WM TRX, 87 nM TRX
reductase, 200 WM NADPH; all from Sigma, Deisenhofen, Germany)
was employed. Enzymatic activity with the TRX system was moni-
tored measuring the decrease of NADPH absorbance at 340 nm with
a microplate reader (Sunrise; Tecan, Crailsheim, Germany). Reduc-
tion of the substrate peptide was in either case measured with mass
spectrometry.
2.3. Mass spectrometry
K-Cyano-4-hydroxycinnamic acid in acetonitrile (saturated solu-
tion) was spotted as 1-Wl droplets onto a sample plate. The dried,
crystalline matrix was crushed with a glass slide, and 1:10 dilutions
(in 33% acetonitrile, 0.1% tri£uoroacetic acid) of the reaction mixes
were spotted onto the matrix. After drying, the samples were washed
twice for 1^2 s with chilled 0.1% tri£uoroacetic acid. Mass spectra
were measured using a Voyager RP_DE1 MALDI-TOF system (Per-
kin-Elmer, Weiterstadt, Germany) in the re£ector mode. For analysis
of enzyme activity, the ratio between the integrated peaks for the
reduced peptide and those for both, the reduced and the oxidized
peptide was calculated.
2.4. Oocyte expression and electrophysiological recording
Coexpression of hCBS1 with the Drosophila ShC/B channel in Xe-
nopus laevis oocytes and current measurements using the two-elec-
trode voltage-clamp technique was performed as described previously
[14,15]. The cbs1 ORF was cloned into the oocyte expression vector
pGEM-HE, and RNA of ShC/B and cbs1 were in vitro transcribed
using a commercially available kit (mMessage mMachine kit; Am-
bion, Austin, TX, USA). Stage V oocytes were injected with 50 nl
of RNAs encoding ShC/B (dilution 1:10) and hCBS1 (dilution 1:4) or
hMSRA (dilution 1:4).
2.5. Tissue distribution of hCBS1
Tissue distribution of cbs1 mRNA was tested utilizing two multiple
tissue expression (MTE) arrays (BD Biosciences) loaded with polyAþ
RNA from 76 di¡erent human tissues and eight di¡erent control
RNAs and DNAs. A PCR fragment covering base pairs 68^548 of
the cbs1 ORF labeled with [K-32P]dATP by random priming (Hart-
mann Analytic, Braunschweig, Germany) was used for hybridization
according to the instructions of the MTE array supplier.
3. Results and discussion
3.1. hCBS1 shows in vitro MSR activity
Overexpression of His6-tagged full-length hCBS1 in E. coli
resulted in insoluble recombinant protein. Removal of the ¢rst
22 amino acids yielded soluble hCBS1v(1-22) protein with an
apparent molecular mass of 19 kDa.
MALDI-MS spectra of the MetO-containing KIFM(O)K
substrate peptide showed a single peak corresponding to its
mass (723 Da). After incubation for 1 h at 37‡C with either
hMSRA or hCBS1 a second peak was detected in the spectra
(Fig. 1A). Its mass (707 Da) was indicative for the reduction
of MetO in the peptide. Additional peaks in some of the
spectra, which could be assigned to the respective peptides
plus Naþ (+22 Da) or Kþ (+38 Da), were included in the
calculation. A peak at 745 Da, consisting of reduced peptide
plus Kþ and oxidized peptide plus Naþ, was excluded. A
maximum reduction of 50^60% was obtained, and enzyme
concentrations required for half-maximal reduction of
200 WM substrate peptide within 1 h were 0.85 WM for
hCBS1 and 0.22 WM for hMSRA. The activity of hCBS1
was thus four-times lower than for hMSRA (Fig. 1B).
With the physiological reductant TRX together with TRX
reductase and NADPH, hCBS1 was also active (Fig. 2A),
indicating that the enzyme, like MSRA, is coupled to the
cellular redox system via TRX. Again, the conversion was
slower as compared to the reduction by hMSRA.
3.2. hCBS1 stereoselectively reduces L-Met-R-SO
Using the TRX system we veri¢ed that hCBS1 constitutes
an MSRB enzyme. The substrate peptide was incubated with
hMSRA until NADPH absorption reached a steady state ¢rst
to reduce L-Met-S-SO (Fig. 2A). Another application of
hMSRA did not result in further NADPH consumption. Ad-
dition of hCBS1 caused a further decrease in absorption and
nearly complete reduction of the substrate peptide, as veri¢ed
by MALDI-MS (Fig. 2A, bottom panel). As MSRA is stereo-
selective for L-Met-S-SO [6], and the peptides used were mix-
tures of both stereoisomers, the most likely interpretation is
that hCBS1 speci¢cally reduced L-Met-R-SO. E. coli YEAA
[9] and mouse SELR [10] also speci¢cally reduce L-Met-R-SO.
The rather weak similarity of hCBS1 to SELR and its human
homolog SELX [16] and the fact that hCBS1 is not a seleno-
protein suggest that two classes of MSRB enzymes are present
in mammals. Sequences with high similarity to hCBS1 are
found in mouse and other animals (BLAST searches, data
not shown).
Fig. 1. MSR activity of hCBS1 with DTT as electron acceptor.
A: MALDI-MS spectra of a synthetic peptide (KIFM(O)K) show a
single peak at a mass of 723 Da. Incubation with hMSRA or
hCBS1 leads to a second peak with a mass di¡erence of 16 Da.
B: Reduction of 200 WM of the synthetic peptide within 1 h in de-
pendence of the enzyme concentration (open circles: hMSRA; ¢lled
circles: hCBS1). n=2^5, meanUmin,max.
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3.3. Identi¢cation of the active site
In order to determine the role of regions displaying se-
quence similarity to either MSRA or to the MSRBs E. coli
YEAA, Neisseria gonorrhoeae PILB, and mouse SELR, we
tested the MetO-reducing activity of three mutants: C105S,
W110A, and C169S. W110 is located in an amino acid stretch
with high similarity to the active site of MSRA (GTGWP in
hCBS1 compared to GCFWG in hMSRA; [12]). It is also
conserved in YEAA proteins [9]. This sequence motif was
therefore proposed to be in the active site of MSRB enzymes
[9] and crystallization of the N. gonorrhoeae PILB-MSRB do-
main indeed con¢rmed this assumption [13]. In bovine MSRA
a W74A mutation resulted in an inactive protein [7]. The
analogous mutation W110A in hCBS1 reduced, but did not
abolish, the enzymatic activity using both DTT and the TRX
system as reductant (Fig. 2B). This observation supports the
assumption that W110 participates in substrate binding, as
proposed for PILB [13].
In the PILB-MSRB domain C440 in the above mentioned
site was shown to be important for its activity with TRX as
reductant [11,13]. hCBS1, however, has no cysteine at that
position (T108) and is yet active. Therefore, a cysteine in
the immediate environment may substitute for the missing
cysteine at position 108. The closest cysteine is C105; how-
ever, when mutated to serine the enzyme showed full activity
both with TRX and DTT (Fig. 2B). Therefore, in hCBS1
either the missing cysteine is replaced by a cysteine di¡ering
from C105 or the reducing activity is based on a di¡erent
mechanism as the one proposed for PILB [11,13].
In all known seleno-proteins the seleno-cysteine is crucial
for their function [17]. The seleno-cysteines in SELR and
SELX correspond to C169 in an alignment with hCBS1.
Thus, residue C169 in hCBS1 may also have an important
function. In fact, mutation C169S in hCBS1 yielded an inac-
tive enzyme irrespective of the reductant used (Fig. 2B). In the
active site of the recently crystallized PILB-MSRB domain
[13], C495, corresponding to C169 in hCBS1, was postulated
to participate in the catalytic conversion of MetO based on
the three-dimensional structure of the protein [13]. In fact,
replacement of C495 also led to an inactive enzyme [11].
Thus, C169 is crucial for the activity of the enzyme and
may also be located in the active site of hCBS1.
3.4. hCBS1 shows in vivo MSR activity
Oxidation of a critical methionine residue (M3) in the
N-terminus of the Drosophila ShC/B channel leads to an im-
Fig. 2. Enzyme activity of hCBS1 and single-site mutants with TRX
as electron acceptor. A: (top) The synthetic peptide KIFM(O)K
was incubated with hMSRA in the presence of the TRX system un-
til NADPH absorbance reached a steady state (open circles). Re-
peated application of hMSRA led to no further NADPH consump-
tion (open squares). Application of hCBS1 resulted in additional
decrease in absorption (¢lled circles). (bottom) Oxidation status of
the substrate peptide as assayed by MALDI analysis of samples tak-
en before, 60 and 120 min after the start of the experiment. While
hMSRA and hCBS1 alone resulted in about 50% reduction, only in-
cubation with both enzymes led to almost complete reduction.
B: Incubation of the substrate with hCBS1 and the indicated mu-
tants in a TRX reduction assay. In the bottom panel the percentage
of reduced peptide is shown for the TRX experiment after 1 h. In
addition, results from parallel experiments using DTT are shown.
While mutation C105S has no impact on enzymatic function,
W110A impairs and C169S completely abolishes the reduction of
MetO-containing peptide. Note that although no peptide was re-
duced with mutant C169S, the NADPH assay indicates some
NADPH consumption.
Fig. 3. E¡ect of MSRs on ShC/B potassium channels expressed in
Xenopus oocytes. Superposition of normalized inactivation time
courses of the ShC/B channel expressed in Xenopus oocytes, elicited
by depolarization of the membrane potential to +40 mV from a
holding potential of 3100 mV. The gray traces are data from indi-
vidual oocytes and the black traces indicate the mean. Coexpression
of ShC/B with hMSRA, hCBS1, or both together is indicated.
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pairment of fast inactivation [14]. This oxidation occurs spon-
taneously and results in ShC/B channel currents with inacti-
vation time courses depending on the condition of the indi-
vidual cells (see Fig. 3, ‘control’). Coexpression of the ShC/B
channel with hMSRA reduces the inactivation variability and
accelerates the overall inactivation time course [14,15]. Like-
wise, coexpression of ShC/B with hCBS1 restored the inacti-
vation time course (Fig. 3), thus providing evidence for the in
vivo activity of hCBS1. Coexpression of hMSRA and hCBS1
did not signi¢cantly increase the e¡ect. Considering that spon-
taneous oxidation of residue M3 results in about equal per-
centage of Met-S-SO and Met-R-SO the e¡ect of hMSRA and
hCBS1 should be additive when M3 of the channel was to
be reduced by these enzymes. Since we did not ¢nd a signi¢-
cant additive e¡ect, we argue that MSRs primarily a¡ect ShC/
B function by protecting the channel from being oxidized,
similarly to an antioxidant, rather than by direct repair of
an oxidized methionine residue in the inactivating ball do-
main.
3.5. hCBS1 is mainly expressed in muscle tissues
hCBS1 expression, as determined by hybridizing two hu-
man multiple tissue polyAþ RNA dot blots with a cbs1-spe-
ci¢c 32P-labeled DNA probe, was observed in virtually all
tissues included in the blot (Table 1). Strongest hybridization
signals were observed in the heart, especially in the ventricles,
and skeletal muscle, followed by liver and kidney. These re-
sults are consistent with Northern blot analyses, which also
indicated high expression of hCBS1 in heart and skeletal
muscle [12]. In the brain hCBS1 expression was weak, whereas
hMSRA expression was very strong, especially in the cerebel-
lum [15]. Both enzymes express in the detoxifying organs liver
and kidney. Di¡erent expression levels of MSRA or MSRB in
some tissues may be explained by the possible presence of
epimerase enzymes with the ability to convert the MetO ster-
eoisomers [18] or the presence of additional, as yet unidenti-
¢ed, MSR variants.
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Table 1
Distribution of hCBS1 mRNA in human tissues
Tissue Expression level relative to ‘whole heart’
(%)
Whole heart 100
Atrium 30
Ventricles 75
Interventr. septum 64
Heart apex 56
Fetal heart 10
Skeletal muscle 56
Liver 53
Kidney 43
Stomach 30
Placenta 20
Whole brain 10
Cerebral cortex 15
Lobes 10
Cerebellum 15
hCBS1 tissue distribution was determined by hybridization of specif-
ic radioactively labeled DNA to an MTE array. Data are estimates
of expression strength, normalized to ‘whole heart’, based on two
MTE arrays.
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